FIELD: chemistry.
SUBSTANCE: invention relates to a method for producing a crystalline form of (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid, including (a) forming a solution including (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid and a mixture of ethyl acetate and water, ethyl acetate or ethanol at an increased temperature; (b) cooling the solution to a temperature between about -20°C and 5°C; and (c) isolating obtained solids with obtaining a crystalline form. The solution from the stage (a) additionally contains a metal acceptor, such as SiliaMetS® Thiol. A temperature at the stage (a) is between about 60°C and 95°C. Isolating solids at the stage (c) includes filtering, washing with one or several solvents, drying in the air or in a vacuum or a combination of these stages. Drying in a vacuum is carried out at a temperature between 25°C and 70°C.
EFFECT: crystalline form of (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid having stability, high melting point and low hygroscopicity.
7 cl, 10 dwg, 9 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
(2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | 2016 |
|
RU2726623C2 |
(2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | 2016 |
|
RU2715241C2 |
SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | 2012 |
|
RU2604522C2 |
NEPRILYSIN INHIBITORS | 2013 |
|
RU2650114C2 |
NEPRILYSIN INHIBITORS | 2011 |
|
RU2605557C2 |
INHIBITORS OF NONPRILYZINE | 2011 |
|
RU2622288C2 |
PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2459809C2 |
NEPRILYSIN INHIBITORS | 2012 |
|
RU2629930C2 |
PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) | 2003 |
|
RU2334513C2 |
Authors
Dates
2021-09-28—Published
2017-03-07—Filed